Repligen (RGEN) Tops Q4 EPS by 2c, Revenues Beat; Offers FY20 EPS/Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Repligen (RGEN) Tops Q4 EPS by 2c, Revenues Beat; Offers FY20 EPS/Revenue Guidance

Repligen Reports Fourth Quarter and Full Year 2019 Financial Results

February 20, 2020 7:30 AM EST

Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growthOverall organic revenue growth was 21% for the fourth quarter and 33% for the year 2019

WALTHAM, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2019. Provided in this press release are financial highlights for the three - and twelve-month periods ended December 31, 2019, followed by our current financial guidance for the year 2020, and... More